From the Department of Health Sciences's Investigation, Sanatorio Metropolitano, Fernando de la Mora, Paraguay; and.
Cardiology Department, First Department of Internal Medicine, Clinic Hospital, Asunción National University, San Lorenzo, Paraguay.
Crit Pathw Cardiol. 2021 Mar 1;20(1):44-52. doi: 10.1097/HPC.0000000000000227.
Due to the lack of prospective, randomized, controlled clinical studies on inflammation and cardiovascular involvement, the exact mechanism of cardiac injury among patients with Coronavirus Disease 2019 (COVID-19) still remains uncertain. It was demonstrated that there is a high and significantly positive linear correlation between troponin T and plasma high-sensitivity C-reactive protein levels, biomarkers of cardiac injury and systemic inflammation, respectively. Cardiac injury and inflammation is a relatively common association among patients hospitalized with COVID-19, and it is related to higher risk of in-hospital mortality. In our literature search, we identified several potential mechanisms of myocardial tissue damage, namely, coronavirus-associated acute myocarditis, angiotensin-converting enzyme 2 receptor binding affinity to the virus Spike protein, increased cytokine secretion, and hypoxia-induced cardiac myocyte apoptosis. Elucidation of the disease pathogenesis and prospective histopathological studies are crucial for future proper treatment in case of renewed outbreaks. Of interest is that with hundred of thousands of bodies available for autopsy studies, no prospective investigation has been reported so far. Strong efforts and continued research of the cardiovascular complications and identification of risk factors for poor prognosis in COVID-19 are steadily needed. The high morbidity and mortality of COVID-19, its monumental economic burden and social impact, the despair of a new pandemic outbreak, and the thread of potential utilization of novel severe acute respiratory syndrome coronavirus 2 as biologic weapons make it a preponderant necessity to better comprehend the therapeutic management of this lethal disease. Emerging as an acute infectious disease, COVID-19 may become a chronic epidemic because of genetic recombination. Therefore, we should be ready for the reemergence of COVID-19 or other coronaviruses.
由于缺乏针对冠状病毒病 2019(COVID-19)患者炎症和心血管受累的前瞻性、随机、对照临床研究,其心脏损伤的确切机制仍不确定。有研究表明,肌钙蛋白 T 与血浆高敏 C 反应蛋白水平之间存在高度显著的正线性相关,分别为心脏损伤和全身炎症的生物标志物。COVID-19 住院患者中,心脏损伤和炎症是相对常见的关联,与住院死亡率升高相关。在我们的文献检索中,我们确定了几种心肌组织损伤的潜在机制,即冠状病毒相关性急性心肌炎、血管紧张素转换酶 2 受体与病毒 Spike 蛋白的结合亲和力、细胞因子分泌增加和缺氧诱导的心肌细胞凋亡。阐明疾病发病机制和前瞻性组织病理学研究对于再次爆发时的正确治疗至关重要。有趣的是,尽管有数十万具尸体可供尸检研究,但迄今为止尚未报道任何前瞻性调查。需要大力且持续研究 COVID-19 的心血管并发症,并确定其不良预后的危险因素。COVID-19 发病率和死亡率高、其对经济和社会的巨大影响、对新的大流行爆发的绝望、以及新型严重急性呼吸系统综合征冠状病毒 2 可能被用作生物武器的潜在利用,使得更好地理解这种致命疾病的治疗管理成为当务之急。COVID-19 作为一种急性传染病,可能因遗传重组而成为慢性流行疾病。因此,我们应该为 COVID-19 或其他冠状病毒的再次出现做好准备。